A practical reference on 肠促胰素: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Approximate composition of the free peptide |
| Molecular weight | Approximately 4813 Da | Calculated for the free base |
| Structural class | Synthetic linear peptide | 39 residues with modified backbone |
| Solubility | Soluble in water and polar solvents | Behavior of the lyophilized solid |
| Typical storage temperature | -20 degrees Celsius or below | Solid form, protected from light |
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
==== Female gonadal development ==== For females, the ovaries become morphologically visible by the 8th week of gestation. The absence of testosterone results in the diminution of the Wolffian structures. The Müllerian structures remain and develop into the fallopian tubes, uterus, and the upper region of the vagina. The urogenital sinus develops into the urethra and lower region of the vagina, the genital tubercle develops into the clitoris, the urogenital folds develop into the labia minora, and the urogenital swellings develop into the labia majora. At 16 weeks of gestation, the ovaries produce FSH and LH/hCG receptors. At 20 weeks of gestation, the theca cell precursors are present and oogonia mitosis is occurring. At 25 weeks of gestation, the ovary is morphologically defined and folliculogenesis can begin. Studies of gene expression show that a specific complement of genes, such as follistatin and multiple cyclin kinase inhibitors are involved in ovarian development. An assortment of genes and proteins - such as WNT4, RSPO1, FOXL2, and various estrogen receptors - have been shown to prevent the development of testicles or the lineage of male-type cells.
As one example, in the 1950s, the Wonder Bread company sponsored the Howdy Doody television show, with host Buffalo Bob Smith telling the audience, "Wonder Bread builds strong bodies 8 ways", referring to the number of added nutrients.
Also, he claimed a brief dispute with The Rock was resolved quickly upon his return, and that none of his disputes with the talent roster continued or played the major part in his departure. In February, Austin returned at No Way Out on February 23 by defeating Eric Bischoff. Austin would wrestle only one match between then and WrestleMania, in another short match against Bischoff on Raw. He entered a feud with The Rock, who returned around the same time as a smug, Hollywood sell-out heel. The Rock was offended that the WWE fans voted for Austin in a WWE Magazine poll to determine the 'Superstar of the Decade'. He expressed his frustration at having never defeated Austin at WrestleMania, and challenged Austin to a match at WrestleMania XIX on March 30. Austin was then defeated by The Rock at WrestleMania XIX, in what would be Austin's final match for 19 years.
== Coffee consumption == As of 2015, there were an estimated 49,600 coffee shops in South Korea, and 17,000 coffee shops in Seoul, making Seoul's coffee-per-capita greater than that of Seattle or San Francisco. The number of coffee shops in South Korea later surpassed 100,000, reaching 100,729 by the end of 2022 according to Statistics Korea—nearly double the combined number of outlets of the country's four largest convenience store chains. South Korea's per capita coffee consumption was estimated at 405 cups per year in 2023, and at 416 cups in 2024, the highest among Asian countries. The instant coffee market makes up a large percentage of the total coffee consumption in Korea where many well-known brands compete for market share. Instant coffee technology like freeze-drying, which was the best method of preserving the flavor of coffee, was improved upon in Korea, where freeze-drying was stabilized for mass production. As of 2003, instant coffee made up 90 percent of all the coffee consumed. With the introduction of big coffee chains like Starbucks, in the late 1990s, the consumption of freshly brewed coffee increased. Going to Starbucks to enjoy coffee became a way to engage with American and Western culture, hence many young and/or middle and upper-middle class Koreans began to frequent Starbucks.
In total, four enzymes are required for the process: three of which are encoded in the dszABC genes (the flavin-dependent monoxygenases DszA and DszC, and the desulfinase DszB) and fourth chromosome encoded enzyme, DszD, which is responsible for the regeneration and supply of the flavin mononucleotide cofactor required for DszA and DszC. It has also been observed that some anaerobic bacteria can use an alternative sulfur-specific pathway to produce hydrogen sulfide instead. However, to date, the desulfurization of fractions such as bitumen, vacuum gas oil, or deasphalted oil has not been observed
Sources: en.wikipedia.org
=== Wilhelmina Fassbinder === Wilhelmina Fassbinder (Georgina Rich) is the ambitious new CFO of Pierpoint, and an early champion of the firm's pivot to ESG. She is frequently at odds with Adler, whose influence she warns Eric not to succumb to. Wilhelmina helps new Pierpoint CEO Tom Wolsey salvage the company's future amid a debt crisis, advocating for an ultimately unsuccessful acquisition by Barclays. After Eric brokers a sale to Al-Mi'raj, a holding company of the Egyptian sovereign wealth fund, at Adler's expense, Wilhelmina retains her title while both Eric and Tom lose their jobs. In series 4, Wilhelmina is now CEO of Al-Mi'raj Pierpoint. The firm has invested in payment processor Tender, which is using Pierpoint's wealth management division as a use case for their new banking app. Wilhelmina agrees to invest a further $1 billion in Tender in the form of a contingent convertible bond after negotiations with CFO Whitney Halberstram. After Tender's stock plummets following rumors of fraud and calls for a new audit, Whitney makes a bid for a hostile takeover of Pierpoint in hopes of complicating regulatory scrutiny, and uses his knowledge that Al-Mi'raj is divesting their ownership of Pierpoint to strong-arm Wilhelmina into allowing him to make an offer at Pierpoint's annual general meeting in New York. However, Wilhelmina later calls Henry and reveals that Whitney never bought a stake in Pierpoint as he previously claimed to Henry, and that she merely used his takeover offer as leverage to sell Pierpoint to Temasek Holdings for a higher price.
Phthalates have been banned from use in feeding bottles in the EU. In the US, there have been repeated calls for the removal of phthalates by the U.S. Consumer Product Safety Commission (CPSC) and others. Their use in children's toys and products was somewhat restricted by the Consumer Product Safety Improvement Act of 2008. Plastics labeled #3 may leach phthalates. Latex rubber nipples may contain phthalates, so silicone nipples may be recommended instead. Packaging may indicate whether a product is "BPA-free" or "phthalate-free". Plastics may degrade over time in other ways, There are concerns that small beads of plastic may be released into fluids from some types of plastic bottles. In 2020 researchers reported that infant feeding bottles made out of polypropylene caused microplastics exposure to infants ranging from 14,600 to 4,550,000 particles per capita per day in 48 regions with contemporary preparation procedures. Microplastics release is higher with warmer liquids and similar with other polypropylene products such as lunchboxes. In 2022, the first study to examine the presence of plastic polymers in human blood found plastics of multiple types in the blood samples of 17 out of 22 healthy adults tested (nearly 80%). Medical experts have suggested reducing exposure to microplastics by not shaking plastic bottles or exposing them to high temperatures. Some recommend using alternative materials such as glass, silicone, or stainless steel.
=== Evaluation of a technique === The technique being evaluated uses voltammetric sensors combined in an electronic tongue (ET) to observe the antioxidant capacity in red wines. These electronic tongues (ETs) consist of multiple sensing units like voltammetric sensors, which will have unique responses to certain compounds. This approach is optimal to use since samples of high complexity can be analyzed with high cross-selectivity. Thus, the sensors can be sensitive to pH and antioxidants. As usual, the voltage in the cell was monitored using a working electrode and a reference electrode (silver/silver chloride electrode). Furthermore, a platinum counter electrode allows the current to continue to flow during the experiment. The Carbon Paste Electrodes sensor (CPE) and the Graphite-Epoxy Composite (GEC) electrode are tested in a saline solution before the scanning of the wine so that a reference signal can be obtained. The wines are then ready to be scanned, once with CPE and once with GEC. While cyclic voltammetry was successfully used to generate currents using the wine samples, the signals were complex and needed an additional extraction stage. It was found that the ET method could successfully analyze wine's antioxidant capacity as it agreed with traditional methods like TEAC, Folin-Ciocalteu, and I280 indexes. Additionally, the time was reduced, the sample did not have to be pretreated, and other reagents were unnecessary, all of which diminished the popularity of traditional methods.
A germline mutation in the reproductive cells of an individual gives rise to a constitutional mutation in the offspring, that is, a mutation that is present in every cell. A constitutional mutation can also occur very soon after fertilization, or continue from a previous constitutional mutation in a parent. A germline mutation can be passed down through subsequent generations of organisms. The distinction between germline and somatic mutations is important in animals that have a dedicated germline to produce reproductive cells. However, it is of little value in understanding the effects of mutations in plants, which lack a dedicated germline. The distinction is also blurred in those animals that reproduce asexually through mechanisms such as budding, because the cells that give rise to the daughter organisms also give rise to that organism's germline. A new germline mutation not inherited from either parent is called a de novo mutation.
Sources: en.wikipedia.org
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.
Single-receptor agents act predominantly at GLP-1R. Tirzepatide retains activity at GIPR, which is expressed in pancreatic islets, adipose tissue, and the central nervous system. The contribution of each receptor to the overall response is still an area of active study, and the relative weight of GIPR signaling in humans is not fully settled.
The fatty diacid moiety binds serum albumin, which reduces renal filtration of the active peptide. Additional resistance to enzymatic breakdown comes from non-natural residues in the backbone. Together these features produce an apparent half-life of about five days and permit weekly dosing intervals.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.